InnoVent
0Providing organisations with specialised IT leasing and life cycle management solutions
#253 of 1802 Developers#336 of 1649 Investors
- Founded in 2003
- Villeneuve-d'Ascq, Hauts-de-France
- 51-200
- innovent.co.za
- za.linkedin.com/company/innovent-rental-&-asset-management-solutions
Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity
05 Jul
Sovereign Wealth Fund Institute
Read on pharmaceutical-technology.comInnovent and IASO Bio enhance collaboration for cell therapy
05 Jul
Sovereign Wealth Fund Institute
Read on seekingalpha.comInnovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
05 Jul
Sovereign Wealth Fund Institute
Read on manilatimes.netIASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy
05 Jul
Sovereign Wealth Fund Institute
Read on manilatimes.netInnovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
02 Jul
Sovereign Wealth Fund Institute
Read on abqjournal.comCould Innovent Biologics' mazdutide be a game-changer in type 2 diabetes treatment?
28 May
Sovereign Wealth Fund Institute
Read on biopharma-reporter.comInnovent:Phase 3 Trial Of Picankibart In Severe Plaque Psoriasis Meets Primary & Key Secondary Goals
28 May
Sovereign Wealth Fund Institute
Read on nasdaq.comInnovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA - Innovent Biologics (OTC:IVBIY)
28 May
Sovereign Wealth Fund Institute
Read on benzinga.comInnovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA By Investing.com
28 May
Sovereign Wealth Fund Institute
Read on uk.investing.comInnovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
28 May
Sovereign Wealth Fund Institute
Read on thelcn.com